Insider Sale: Joseph L. Moskowitz Disposes 1,000 AFL Shares
Rhea-AI Filing Summary
Joseph L. Moskowitz, identified as a Director of Aflac Inc., reported the sale of 1,000 shares of Aflac common stock on 08/08/2025 at a price of $102.57 per share. After the reported transaction the filing shows he beneficially owned 25,105 shares. The Form 4 indicates it was filed by one reporting person and bears a signature date of 08/12/2025.
The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2024. No derivative transactions are reported in the document, and the form includes the reporting person's address and role. The disclosure is limited to the transactions described and the plan referenced.
Positive
- Sale executed under a Rule 10b5-1 trading plan (adopted December 4, 2024), indicating the trades were pre-arranged under an approved plan.
- Form 4 filed and signed (signature dated 08/12/2025) documenting the transaction and meeting disclosure requirements.
Negative
- None.
Insights
TL;DR: Director sold 1,000 AFL shares under a pre-arranged 10b5-1 plan; the transaction is documented and appears routine.
The Form 4 reports a single non-derivative sale of 1,000 Aflac shares on 08/08/2025 at $102.57 per share, leaving 25,105 shares beneficially owned. The sale was executed under a Rule 10b5-1 plan adopted on December 4, 2024, which indicates the trades were pre-authorized rather than opportunistic. No options, warrants, or other derivative positions are listed, limiting complexity. Based solely on the filing, the disclosure is routine and provides required transparency to investors.
TL;DR: Filing shows adherence to insider-trading protocols with a disclosed 10b5-1 plan and timely Form 4 reporting.
The report identifies Joseph L. Moskowitz as a director and documents the sale as effected pursuant to a Rule 10b5-1 plan dated December 4, 2024. The Form 4 was signed on 08/12/2025, following the 08/08/2025 transaction. These elements reflect compliance with disclosure requirements and the use of an approved trading plan. The filing contains no indications of amendments, derivative transactions, or other governance concerns within the provided text.